Aim: To evaluate the impact of corticosteroid therapy during the late preterm period on maternal and fetal. Material and Methods: A total of 100 antenatal patients between 34 and 36.6 weeks of gestation, who were likely to deliver preterm, were included in the study. These patients were randomly divided into two groups of 50 each: Group A (Cases) and Group B (Controls). Group A received two doses of Betamethasone 12 mg administered 12 hours apart, while Group B did not receive any placebo. The two groups were matched for maternal age, gestational age, parity, and comorbidities to ensure comparability.The demographic profile of the patients was studied in detail. The patients were included irrespective of the mode of delivery. After delivery, the neonates were closely monitored for several parameters. These included the duration of NICU stay, incidence of respiratory distress (noted by signs such as grunting, retractions, and nasal flaring), incidence of necrotizing enterocolitis, incidence of intraventricular hemorrhage, incidence of transient tachypnea of the newborn, APGAR scores, the need for oxygen therapy (administered via hood or supplemental nasal cannula), need for surfactant administration, requirement for artificial ventilation, and incidence of neonatal hypoglycemia. Results: Neonatal outcomes, as presented in Table 2, indicate significant differences between the two groups. The mean duration of NICU stay was significantly shorter in Group A (5.2 ± 2.1 days) compared to Group B (7.4 ± 3.2 days) with a p-value of 0.03. The incidence of respiratory distress was also lower in Group A (16%) than in Group B (30%), with a significant p-value of 0.04.Necrotizing enterocolitis occurred in 2% of neonates in Group A and 6% in Group B, although this difference was not statistically significant (p=0.30). Intraventricular hemorrhage was reported in 0% of Group A and 4% of Group B (p=0.24). The incidence of transient tachypnea of the newborn was lower in Group A (10%) compared to Group B (24%) with a borderline significant p-value of 0.05. APGAR scores at 1 minute and 5 minutes were significantly higher in Group A (7.5 ± 0.7 and 8.8 ± 0.6, respectively) compared to Group B (6.8 ± 0.9 and 8.2 ± 0.7), with p-values of 0.02 and 0.04, respectively.Maternal outcomes are summarized in Table 5. The rate of cesarean delivery was slightly lower in Group A (30%) compared to Group B (36%), but this was not statistically significant (p=0.52). Postpartum infections occurred in 4% of Group A and 8% of Group B (p=0.68). The incidence of hyperglycemia requiring treatment was 10% in Group A and 6% in Group B (p=0.71). Maternal psychological well-being, as measured by a mean score, was higher in Group A (8.5 ± 1.2) compared to Group B (7.8 ± 1.5), though not significantly different (p=0.21). Conclusion: In conclusion, the administration of Betamethasone in the late preterm period significantly improves neonatal outcomes, particularly by reducing NICU stay and respiratory distress. While there are some risks associated with maternal hyperglycemia, the overall benefits for neonatal and maternal health are substantial.